Japanese firm acquires Israeli pharmaceutical company NeuroDern Print

Israeli pharmaceuticals company NeuroDerm Ltd has been sold for US$$1.1 billion. The buyer is Japanese company Mitsubishi Tanabe Pharma Corporation (MTPC). The transaction is the largestever acquisition of an Israeli healthcare company, and one of the largest acquisitions of an Israeli company of any kind.

NeuroDerm is a clinicalstage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders. The acquisition by MTPC has received unanimous approval by NeuroDerm’s board of directors. Assuming typical regulatory and shareholder approval timeframes, NeuroDerm anticipates that the transaction will close in the fourth quarter of this year.

“We believe that this transaction will yield important benefits for NeuroDerm’s shareholders and the Parkinson’s disease patients who urgently need new therapies,” said Dr Oded Lieberman, CEO of NeuroDerm. “MTPC has demonstrated development and commercialisation expertise in the field of neurology and we are confident that the combination of their resources and the robust data supporting ND0612, our Phase III Parkinson’s disease product candidate, will help make this important new therapy available as broadly and rapidly as possible.”

(Issue Sep 2017)